ANI ends royalties to Teva for $16M

On January 30, 2019, ANI Pharmaceuticals, Inc. (the “Company”) entered into Amendment No. 4 to its Asset Purchase Agreement (the “Purchase Agreement Amendment”) with Teva Pharmaceuticals USA, Inc. (“Teva”). Under the terms of the Purchase Agreement Amendment, all royalty obligations of the Company owed to Teva with respect to products associated with ten ANDAs under the Asset Purchase Agreement shall cease effective as of December 31, 2018. In consideration for the termination of such future royalty obligations, the Company agreed to pay Teva a sum of $16,000,000.

https://www.marketscreener.com/ANI-PHARMACEUTICALS-INC-13658425/news/ANI-PHARMACEUTICALS-INC-Entry-into-a-Material-Definitive-Agreement-form-8-K-27951117/